Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 228.5%

by · The Cerbat Gem

Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 497,000 shares, an increase of 228.5% from the November 30th total of 151,300 shares. Currently, 5.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,660,000 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $7.00 price objective on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

View Our Latest Report on WINT

Windtree Therapeutics Price Performance

Shares of NASDAQ WINT opened at $0.31 on Thursday. The business has a 50-day moving average of $0.57 and a 200-day moving average of $3.40. The company has a market capitalization of $2.79 million, a price-to-earnings ratio of -0.02 and a beta of 0.54. Windtree Therapeutics has a 1-year low of $0.29 and a 1-year high of $14.75.

Windtree Therapeutics Company Profile

(Get Free Report)

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.

Read More